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Introduction. Requirement of permanent pacemaker (PPM) implantation is a known and common postoperative consequence of
transcatheter aortic valve replacement (TAVR). The Emory risk score has been recently developed to help risk stratify the need for
PPM insertion in patients undergoing TAVR with SAPIEN 3 valves. Our aim was to assess the validity of this risk score in our
patient population, as well as its applicability to patients receiving self-expanding valves. Methods. We conducted a retrospective
review of 479 TAVR patients without preoperative pacemakers from November 2016 through December 2018. Preoperative risk
factors included in the Emory risk score were collected for each patient: preoperative QRS, preoperative right bundle branch block
(RBBB), preoperative syncope, and degree of valve oversizing. Multivariable analysis of the individual variables within the scoring
system to identify predictors of PPM placement was performed. The predictive discrimination of the risk score for the risk of PPM
placement after TAVR was assessed with the area under the receiver operating characteristic curve (AUC). Results. Our results
demonstrated that, of the 479 patients analyzed, 236 (49.3%) received balloon-expandable valves and 243 (50.7%) received selfexpanding valves. Pacemaker rates were higher in patients receiving self-expanding valves than those receiving balloonexpandable valves (25.1% versus 16.1%, p � 0.018). The Emory risk score showed a moderate correlation with pacemaker
requirement in patients receiving each valve type, with AUC for balloon-expandable and self-expanding valves of 0.657 and 0.645,
respectively. Of the four risk score components, preoperative RBBB was the only predictor of pacemaker requirement with an
AUC of 0.615 for both balloon-expandable and self-expanding valves. Conclusion. In our cohort, the Emory risk score had modest
predictive utility for PPM insertion after balloon-expandable and self-expanding TAVR. The risk score did not oﬀer better
discriminatory utility than that of preoperative RBBB alone. Understanding the determinants of PPM insertion after TAVR can
better guide patient education and postoperative management.

1. Introduction
Transcatheter aortic valve replacement (TAVR) is now an
established alternative to surgical aortic valve replacement
for patients with severe aortic stenosis [1–4]. Despite its
success and limited complication risk, the occurrence of
conduction abnormalities and the need for permanent
pacemaker (PPM) implantation remain the most frequent
complication of TAVR [5].
Many studies have identiﬁed predictors of PPM implantation following TAVR [6–8]. Most recently, Kiani et al.

developed the Emory risk score as a tool to aid in the risk
stratiﬁcation of patients undergoing TAVR with SAPIEN 3
balloon-expandable valves. The characteristics of the score
include history of syncope, preexisting right bundle branch
block (RBBB), QRS duration ≥140 ms, and valve oversizing
≥16% [9].
The aim of this study is to assess the validity of the
Emory risk score in our patient population. Moreover,
we sought to determine whether the model was applicable to both balloon-expandable and self-expanding
valves.
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2. Methods
This study was conducted with the approval of the Northwell
Health System Institutional Review Board. As this is a
retrospective study utilizing de-identiﬁed data collected
from the New York State and STS databases, speciﬁc waiver
of the need for individual patient consent was granted by the
Institutional Review Board.
All patients who underwent TAVR for severe, symptomatic aortic stenosis from October 2016 to December 2018
were included in this study. All patients were implanted with
either a Medtronic Evolut (Medtronic, Minneapolis, MN) or
Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, CA) valve.
Patients with preexisting PPM or implanted cardiac deﬁbrillators or those undergoing a valve-in-valve procedure
were excluded. Preoperative characteristics included in the
Emory risk score were collected for each patient, including
preoperative QRS duration, preoperative RBBB, the presence of syncope as a symptom, and degree of valve oversizing. A risk score of 0–5 was calculated for each patient,
with 1 point allocated for QRS ≥140 ms, syncope, and valve
oversizing of ≥16%, and 2 points allocated for preoperative
RBBB.
The following baseline preoperative data were also
collected for each patient: age, gender, valve type, valve size,
Society of Thoracic Surgery Predicted Risk of Mortality
(STS-PROM), operator risk stratiﬁcation, and other risk
factors and comorbidities (i.e., dialysis, creatinine, cerebrovascular disease, peripheral artery disease, New York
Heart Association heart failure class, diabetes, body mass
index, and preoperative ejection fraction). The primary
clinical endpoint of interest was the requirement of PPM
post-TAVR.
Continuous variables are expressed as mean ± standard
deviation and compared using Student’s t-test. Categorical
variables are expressed as percentages and compared using the
chi-square test or Fisher’s exact test, where appropriate. Differences in preoperative characteristics between patients who
required PPM and those who did not were assessed. The association of each individual risk factor with the requirement of
PPM was assessed using multivariable logistic regression
analysis for both balloon-expandable and self-expanding
valves. The accuracy of the Emory risk score and individual
factors were assessed with area under receiver-operating
characteristic (ROC) curve. Data analysis was performed retrospectively. All statistical analyses were performed using SAS
Version 9.4 (SAS Institute Inc., Cary, NC).

3. Results
Preoperative characteristics and risk factors, including the
components of the Emory risk score, are presented in Table 1. Of the 479 patients who underwent TAVR, 99 (20.7%)
patients required PPM. Of the patients that underwent PPM,
86 (86.9%) patients required a pacemaker during the index
TAVR admission, and 13 (13.1%) patients required a
pacemaker following discharge. Among the entire cohort,
236 (49.3%) received balloon-expandable valves and 243
(50.7%) received self-expanding valves. Thirty-eight (16.1%)
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Table 1: Baseline patient characteristics: post-TAVR PPM versus
no PPM.
Preoperative characteristics
Male
Age, years
Valve type
Self-expanding
Balloon-expandable
RBBB
QRS duration
QRS >140 ms
Valve oversizing, %
Valve oversizing >16.0%
Syncope
Emory risk score
Score � 0
Score � 1
Score � 2
Score � 3
Score � 4
Score � 5
STS-PROM, %
Operator stratiﬁcation
Low risk
Intermediate risk
High risk
Heart failure (NYHA)
Class II
Class III
Class IV
Ejection fraction, %
Albumin, g/dL
Creatinine, mg/dL
Dialysis
Cerebrovascular disease
Peripheral artery disease
Diabetes
Body mass index

No PPM
N � 380
169 (44.6)
82.3 ± 7.8

PPM
p value
N � 99
52 (52.5)
0.158
82.2 ± 10.5 0.960
0.015
182 (47.9)
61 (61.6)
—
198 (52.1)
38 (38.4)
—
29 (7.7)
30 (30.3) <0.001
99.5 ± 23.7 115.3 ± 27.6 <0.001
35 (9.2)
23 (23.2) <0.001
12.91 ± 10.26 14.62 ± 9.83 0.136
215 (56.6)
53 (53.5)
0.586
13 (3.4)
5 (5.1)
0.447
<0.001
178 (46.8)
32 (32.3)
—
159 (41.8)
32 (32.3)
—
23 (6.1)
12 (12.1)
—
14 (3.7)
15 (15.2)
—
6 (1.6)
8 (8.1)
—
0 (0.0)
0 (0.0)
—
6.2 ± 6.1
6.3 ± 3.6
0.901
0.692
1 (0.3)
0 (0.0)
—
206 (54.2)
49 (50.0)
—
171 (45.0)
49 (50.0)
—
0.595
102 (26.9)
22 (22.2)
—
252 (66.5)
69 (69.7)
—
25 (6.6)
8 (8.1)
—
61.8 ± 13.4 60.4 ± 13.5 0.352
3.9 ± 0.7
3.9 ± 0.7
0.942
1.3 ± 1.3
1.6 ± 1.7
0.079
13 (3.4)
4 (4.0)
0.766
23 (6.1)
8 (8.1)
0.465
53 (13.9)
13 (13.1)
0.833
125 (32.9)
32 (32.3)
0.914
27.9 ± 5.9
28.4 ± 6.8
0.498

Continuous factors are given as mean (±standard deviation), compared
using Student’s t-test. Frequency and percent are given for categorical
factors, compared using the chi-square test. NYHA � New York Heart
Association; PPM � permanent pacemaker implantation; RBBB � right
bundle branch block; STS-PROM � Society of Thoracic Surgeons Predicted
Risk of Mortality.

of patients receiving balloon-expandable valves required
PPM, while 61 (25.1%) of patients receiving self-expanding
valves required PPM (p � 0.015).
The incidence of the elements included in the risk score
among all patients was as follows: 12.3% of the patients had
RBBB, 12.1% had a QRS duration ≥140 ms, 56% had valve
oversizing ≥16%, and 3.8% had a history of syncope. Patients
who required PPM post-TAVR were more likely to have
preoperative RBBB (30.3% versus 7.7%, p < 0.001), had
longer mean QRS duration (115.3 ± 27.6 versus 99.5 ± 23.7,
p < 0.001), and were more likely to have a QRS duration
≥140 ms (23.2% versus 9.2%, p < 0.001). There was no signiﬁcant diﬀerence in valve oversizing, presence of preoperative syncope, and other demographics and comorbidities
between patients that received PPM versus those that did
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not. Patients who required PPM after TAVR had a higher
Emory risk score as compared to those who did not require
PPM (p < 0.001, Table 1).
The components of the Emory risk score assessed using
multivariable analysis by valve type are presented in Table 2.
Of the four risk score components, preoperative RBBB was
the only independent predictor of pacemaker requirement,
regardless of valve type. Among patients receiving balloonexpandable valves, 41.4% of patients were with RBBB-required pacemakers (OR 3.89, p � 0.010); among those receiving self-expanding valves, 60.0% of patients were with
RBBB-required pacemakers (OR 5.75, p < 0.001). Although
QRS ≥140 ms was associated with PPM insertion after
TAVR in the univariate analysis, it was no longer signiﬁcant
in the multivariable analysis for both valve types.
The area under the ROC curve for the Emory risk score
to discriminate for patients requiring PPM after TAVR was
0.645 for balloon-expandable valves (Figure 1) and 0.657 for
self-expanding valves (Figure 2). The area under the ROC
curve for the preoperative RBBB to discriminate for patients
requiring PPM after TAVR was 0.615 for both balloonexpandable and self-expanding valves. The Emory risk score
did not demonstrate signiﬁcant superiority in discriminatory power over the presence of RBBB alone in predicting
post-TAVR PPM requirements (p � 0.350 for balloon-expandable valves and p � 0.151 for self-expanding valves).

4. Discussion
Our results demonstrated that the Emory risk score, which
stratiﬁes patients based on QRS duration, preexisting RBBB,
preoperative syncope, and valve oversizing have similar
discriminatory ability for need for PPM after TAVR for
balloon-expandable and self-expanding valves. The risk
score, however, does not provide signiﬁcantly increased
discriminatory power over presence of preoperative RBBB
alone.
The Emory risk score is the ﬁrst contemporary scoring
system to predict the need for PPM among patients undergoing TAVR [9]. It was developed by Kiani et al. and
derived from data from a single institution undergoing
Edwards SAPIEN 3 valves. It incorporates four characteristics: history of syncope, right bundle branch block, QRS
duration ≥140 ms, and valve oversizing ≥16%. Kiani et al.
reported an area under the curve for their Emory risk score
of 0.778 in the validation cohort of patients undergoing
SAPIEN 3 valves. Our study is the ﬁrst to apply the Emory
risk score to patients receiving Evolut balloon-expandable
valves. While we found that the Emory risk score has similar
discriminatory utility for risk of PPM after TAVR for both
balloon-expandable and self-expanding valves, the area
under the curve from our patient sample was signiﬁcantly
lower than that obtained by Kiani et al. (0.615 for both
balloon-expandable valves and self-expanding valves). Differences in implant technique and institutional guidelines
for PPM after TAVR may account for the diﬀerences in
discriminatory utility of the risk score. This highlights the
diﬃculty in developing universal risk scoring algorithms as
algorithms developed in one institution may not be
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applicable to other institutions secondary to diﬀerences in
practice patterns.
Incidence of elements of the risk score may vary by
institution, further complicating the development of a
universal algorithm. This is particularly true in elements of
the risk score that are operator dependent. For instance, the
incidence of valve oversizing ≥16% was substantially higher
in our cohort relative to the Emory derivation cohort (56%
versus 23.6%), highlighting likely diﬀerences in the valve
type and size selection. Notwithstanding, studies have shown
that >20% oversizing in self-expanding valves does not
signiﬁcantly increase the rate of PPM insertion [10]; thus, we
do not believe that this variation would explain the diﬀerences in our outcomes. Further, the incidence of history of
syncope was lower in our cohort (3.8% versus 9.4%). While
lower than the Emory study, this remains consistent with the
literature [11]. The incidence of RBBB (12.3% versus 15.6%)
and QRS duration ≥140 ms (12.1% versus 13.6%) were
comparable between our cohort and the derivation cohort in
the Emory study.
In our sample, 20.7% of patients required PPM implantation after TAVR. In patients receiving balloon-expandable valves, the PPM rate was 16.1% versus 25.1% in
self-expanding valves. The ﬁnding that PPM insertion rate is
higher in patients receiving self-expanding valves is consistent with the literature. Previously published studies have
shown the PPM rate to be as high as 17% for balloon-expandable valves [12] and 40% for self-expanding valves [13].
Preoperative RBBB was the only independent predictor of
PPM implantation in our cohort, regardless of valve type.
This is consistent with existing literature in which preoperative RBBB has been shown to be a well-described predictor of postoperative PPM implantation. In our study,
preoperative RBBB oﬀered similar discriminatory utility for
need for PPM after TAVR as the Emory risk score [6, 14, 15].
While QRS duration was found to be a signiﬁcant predictor
of PPM on univariate analysis, there was no signiﬁcance on
multivariable analysis. This is likely due to the association
between QRS duration and RBBB. Valve oversizing was not
an independent predictor of PPM in our study, which is
consistent with prior literature [16, 17], albeit not consistent
with the Emory study. Similarly, while syncope is an independent predictor of need for PPM in the Emory risk
score, we did not ﬁnd it to be an independent predictor in
our study. The low prevalence of syncope in our patient
population may not have provided adequate statistical
power to show signiﬁcance.
There are other electrical, procedural, and anatomical
factors that have been shown to be associated with an increased need for PPM after TAVR including ﬁrst-degree
heart block, implantation depth, length of the membranous
septum, pre and postdilation of the prosthesis, and aortic
annulus calcium score [18–22]. Our current study did not
evaluate the association of such factors with PPM insertion
as the primary objective of this study was to validate the
Emory risk score which does not incorporate such factors.
There are several limitations to this study that should be
acknowledged. First, there are no speciﬁc recommendations
for PPM implantation after TAVR. Decisions to proceed
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Table 2: Multivariable analysis of predictors of postoperative PPM rates, by valve type.

Variable
Oversize >16%
Baseline RBBB
Baseline QRS >140 ms
History of syncope
AUC of Emory risk score

Balloon-expandable
OR (95% CI)
1.58 (0.66, 3.83)
3.63 (1.31, 10.05)
1.84 (0.62, 5.45)
1.93 (0.42, 8.91)
0.645

p value
0.310
0.013
0.270
0.400

Self-expanding
OR (95% CI)
0.61 (0.32, 1.16)
5.57 (2.20, 14.10)
1.15 (0.43, 3.06)
1.36 (0.26, 7.07)
0.657

p value
0.134
<0.001
0.780
0.710

Odds ratios are given with 95% conﬁdence interval. AUC � area under curve; PPM � permanent pacemaker implantation; RBBB � right bundle branch block.
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Figure 1: ROC curve for balloon-expandable valves.

This may lead to type II error when evaluating the association of the speciﬁc criteria with requirement for PPM.
However, the main objective of this study was to validate the
Emory risk score, not the individual predictors of PPM
placement. Third, although all clinical information relevant
to the Emory risk score was independently validated for the
purpose of this study, the study remains retrospective in
nature and, therefore, has all the limitations of a retrospective study. Fourth, patients in this study received either
SAPIEN 3 or Evolut valves. PPM implantation rate varies by
both valve type and generation. The new-generation SAPIEN 3 valves have been associated with higher PPM implantation rates relative to the old-generation SAPIEN XT
valves [23]. In contrast, the new-generation Evolut valves
have lower PPM rates as compared with their ﬁrst-generation counterparts [24]. As such, the results of this study
may not be applicable to valve types and/or generations that
are not utilized in our study population. Finally, as with all
single-center studies, the results of this study may not be
generalizable to other institutions. In fact, our ﬁnding that
the Emory risk score displayed signiﬁcantly less discriminatory utility in our patients as compared to its original
validation cohort highlights this limitation.

1.00

5. Conclusions
In our cohort, the Emory risk score had modest predictive
utility for PPM insertion after TAVR for both balloon-expandable and self-expanding prostheses. The risk score did
not oﬀer better discriminatory utility than that of preoperative RBBB alone.
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The data used to support the ﬁndings of this study are
available from the corresponding author upon request.
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Figure 2: ROC curve for self-expanding valves.

with PPM may therefore be subject to selection bias. Second,
while our overall sample size was large, the subset of patients
who met speciﬁc criteria of the risk score was more limited.
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